Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study
June 11 2019 - 7:25AM
Dow Jones News
By Colin Kellaher
Roche Holding AG's (ROG.EB) Genentech unit Tuesday said a phase
II study of Gazyva met its primary and key secondary endpoints in
adults with the kidney disorder proliferative lupus nephritis.
Genentech said Gazyva in combination with standard of care
showed enhanced efficacy compared to placebo plus standard of care
alone in achieving complete renal response at one year.
Gazyva also showed improved overall renal responses and
serologic markers of disease activity compared to placebo, the
company said.
Genentech said there are currently no FDA-approved therapies for
lupus nephritis, a potentially life-threatening condition in which
patients are at high risk for progressing to end-stage renal
disease or death.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 11, 2019 07:10 ET (11:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
